October 2020
Zydus Cadila has received final approval from the USFDA to market Solifenacin Succinate Tablets, (US RLD: Vesicare®Tablets) in the strengths of5 mg and 10 mg. Solifenacin Succinateis a symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.
The group now has 309 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.
Subscribe to PharmaTutor News Alerts by Email
Knowing you have developed antibodies against the SARS-CoV-2 virus after recovering from COVID-19 doesn't tell you everything about your immunity. The levels and even types of antibodies can differ among patients, and those differences can influence whether a person is protected against being reinfected.
Research led by Queen Mary University of London has revealed novel insights into the mechanisms employed by melanoma cells to form tumours at secondary sites around the body. The findings from the study may help to identify new targets to inhibit melanoma spread and guide treatment decisions in the clinic.
RECOMMENDED POSTS
Subscribe with us
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
Also Join: 
.png)
